Consensus ZyVersa Therapeutics, Inc.

Equities

ZVSA

US98987D3008

Real-time Estimate Cboe BZX Other stock markets 02:10:30 2024-05-22 pm EDT			5-day change	1st Jan Change
4.495 ^USD	+2.16%		-9.92%	-50.56%

Mar. 25	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease	CI

Evolution of the average Target Price on ZyVersa Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d96b91585f9613fe8844.c3fQuinYM1fV5yjHO76py6O5GaRYMFuh86PrY8_3Plc.Gzzn3BGVa2fkrUqCCNr7qJfeIZc6Xx3zos6NK7-gYSAlBoHCSqtkMOKtXw~b55aeacfffbd76809ddd9512ba992ce9

Analyst Recommendations on ZyVersa Therapeutics, Inc.

HC Wainwright Cuts Price Target on ZyVersa Therapeutics to $12 From $24, Maintains Buy Rating	Mar. 12	MT
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	23-09-08	MT
HC Wainwright Starts ZyVersa Therapeutics With Buy Rating, Price Target is $2.50	23-09-08	MT
ZyVersa Therapeutics, Inc. Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease	23-05-15	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.4 USD

Average target price

70 USD

Spread / Average Target

+1,490.91%

High Price Target

120 USD

Spread / Highest target

+2,627.27%

Low Price Target

20 USD

Spread / Lowest Target

+354.55%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ZyVersa Therapeutics, Inc.

HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar